Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.60 |
| ▸ | LPL | P06858 | 2/20 | 0.54 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051196 | 0.87 | ENPP2 (0.58) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL20780633 | 0.84 | ENPP2 (0.55) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL21125600 | 0.81 | LPL (0.60) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL4618032 | 0.81 | ENPP2 (0.51) | ENPP2LPLLIPGMGLLEPHX1 | |
| SCHEMBL29165967 | 0.79 | ENPP2 (0.53) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL8539519 | 0.79 | GABRA1 (0.50) | GABRA1GABRB2PNMT | |
| SCHEMBL692342 | 0.78 | ENPP2 (0.67) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL6358240 | 0.78 | ENPP2 (0.51) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL29950926 | 0.78 | ENPP2 (0.51) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL5872608 | 0.77 | ENPP2 (0.72) | ENPP2LPLLIPGKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024228035-A1 | IKK-ALPHA INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-11-07 | — | — | WO | disclosed |
| US-20240107872-A1 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-03-28 | — | — | US | disclosed |
| EP-3341385-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2020-03-11 | — | — | EP | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-RE47415-E1 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170327517-A1 | Boronic Acid Inhibitors of HIV Protease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-16 | — | — | US | disclosed |
| US-20170305893-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-10-26 | — | — | US | disclosed |
| US-20170305893-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-10-26 | — | — | US | disclosed |
| US-9738664-B2 | Boronic acid inhibitors of HIV protease | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8748623-B2 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-6673824-B1 | HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB CO. | 2004-01-06 | — | — | US | disclosed |
| US-6107320-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0569193-B1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | SQUIBB & SONS INC (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0569193-A1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305893-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | DCTPP1, ENPP1, PPA1 | ENPP2 274/4885LPL 2499/4885LIPG 3346/4885 |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | CXCR2, CXCR1, CXCR3 | ENPP2 277/4885LPL 3097/4885LIPG 2110/4885 |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | CXCR2, CXCR1, CXCR3 | ENPP2 250/4885LPL 3723/4885LIPG 2689/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | ENPP2 1920/4885LPL 3816/4885LIPG 3010/4885 |
| US-20170327517-A1 | Boronic Acid Inhibitors of HIV Protease | PREP, DNPEP, PEPD | ENPP2 892/4885LPL 2408/4885LIPG 2171/4885 |
| US-20240107872-A1 | Metal complexes | MCU, IMMT, SOD1 | ENPP2 1910/4885LPL 4017/4885LIPG 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.